Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia. The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral therapy, as well as for the treatment of tumor, autoimmune, metabolic diseases, and other therapeutic fields. It also develops GB05, a human interferon a1b inhalation solution that is in Phase III clinical trial; GB-K02, a human granulocyte colony-stimulating factor injection in Phase III clinical trial; GB08, a growth hormone that has completed Phase I clinical trial; GB10 for fundus diseases; GB12 for atopic dermatitis; GB18 for cancer cachexia; GB23 for solid tumors; GB24 for inflammatory bowel diseases; and GB25, a tri-specific antibody for colorectal cancer. In addition, the company's products include drugs, such as human erythropoietin, human interferon a1b and human granulocyte colony-stimulating factor injections, albumin-bound paclitaxel, infliximab injection, combined clostridium butyricum, apaltamethasone tablets, infliximab for injectio, ahrasin (adalimumab injection), liraglutide injection, smegglutide injection, boyoubi and bologna denosumab injection, nolantai, sevelam carbonate tablets, abersipu, sitagliptin phosphate tablets, propofol emulsion injection, teriparatide injection, tamsulosin hydrochloride extended-release capsules, oseltamivir phosphate dry suspension, and bifidobacterium powder/capsule. Kexing Biopharm Co., Ltd. was founded in 1997 and is based in Jinan, China.